VRAY - Aspira extends gains as analysts weigh in; Flexion to benefit from Pfizer's failure in osteoarthritis drug and more in today's analyst action

Aspira Women's Health (AWH) has extended the post-market gains with a ~12.2% rise in the pre-market as analysts weigh in on its new agreement to develop an early detection test for ovarian cancer.“We support the notion of the team taking another big swing and working to enter a market that is in desperate need for an early detection test,” even though the product could be “a few years away,” a William Blair analyst wrote.Implying ~78.8% upside to the previous close Cantor Fitzgerald has raised the price target of the stock to $12.00 from $10.00 per share. OvaSight test “will have a solid impact on the company’s performance in 2022 and beyond,” the analyst argues.Both firms have buy-equivalent ratings on the stock.Flexion Therapeutics (FLXN) which has lost ~17.9% in the year so far, rose ~4.9% yesterday as osteoarthritis drug Tanezumab developed by Pfizer (PFE) and Eli Lilly (LLY) failed to win the endorsement from an FDA

For further details see:

Aspira extends gains as analysts weigh in; Flexion to benefit from Pfizer’s failure in osteoarthritis drug and more in today’s analyst action